Ym Biosciences Australia Pty Ltd.

Gilead Sciences, Inc.

Michael Francis Harte

Christopher John Burns

Andrew Frederick Wilks

Harrison Sikanyika

Emmanuelle Fantino

James T Palmer

Colette Gloria Sims

Xianyong Bu

Compounds of general formula (I), (II), (III) and (V) are described for use in modulating microtubule polymerization and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II), (III) and (V). 

Substituted 1,2,4-triazines as tubulin inhibitors

Substituted pyrazines as tubulin inhibitors

Pyridine derivatives useful as kinase inhibitors

Substituted pyrazines as inhibitors of kinase activity

Compounds of general formula (I), (II), (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II), (III) and (V). 

2-phenyl pyrazines as tubulin inhibitors

A compound of general formula (I) or pharmaceutically acceptable prodrugs, salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating a hyperproliferation-related disease state or disorder in a subject using a compound of formula (I) is also described. 

Pyrazine-based tubulin inhibitors

Compounds of general formula (I), (II) (III) and (V) are described for use in modulating microtubule polymerisation and in the treatment of associated disease states. Use of compounds (I), (III) and (V) in the treatment of kinase-associated disease states is also described. Further described are novel compounds of formula (II), (III) and (V). 

2-phenyl pyrimidines which are tubulin inhibitors

Growing community of inventors

Viewbank, Australia

Michael Francis Harte